Journal article
Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery
American journal of obstetrics and gynecology, v 193(3), pp 1181-1186
2005
PMID: 16157134
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The purpose of this study was to examine the utility of a single second-trimester plasma corticotropin-relasing hormone measurement as a marker for preterm delivery in women at high risk for preterm delivery.
This is an analysis of data from a multicenter placebo-controlled trial designed to evaluate the role of 17 alpha hydroxyprogesterone caproate (17P) in the prevention of recurrent preterm birth. Women with a documented history of a previous spontaneous preterm birth at <37 weeks were enrolled (16-20 wks) and randomly assigned in a 2 to 1 ratio to weekly injections of 17P or matching placebo. Blood was collected before treatment in 170 patients (113 assigned 17P and 57 placebo) who were enrolled at 11 of the 19 centers. Plasma levels of corticotropin-releasing hormone were compared between those who delivered preterm and those delivering at term. Data were analyzed using the Wilcoxon rank-sum test.
The overall rates of preterm birth in this cohort of 170 patients were 35.9% at <37 weeks (31.9% progesterone, 43.9% placebo), and 19.4% at <35 weeks (18.6% vs 21.1%). The median levels of corticotropin-releasing hormone were similar between those delivering at <37 weeks and those delivering ≥37 weeks (0.39 ng/mL vs 0.37 ng/mL,
P
=
.08). In addition, there were no differences in corticotropin-releasing hormone levels among those who delivered at <35 weeks or ≥35 weeks (0.36 vs 0.38,
P
=
.90). Moreover, there were no differences in corticotropin-releasing hormone levels among those in the placebo group who delivered at <37 or ≥37 weeks (0.40 vs 0.41,
P
=
.72) and at <35 or ≥35 weeks (
P
=
.64).
A single measurement of corticotropin-releasing hormone at 16 to 20 weeks' gestation is not a good biomarker for recurrent preterm delivery in patients at high risk for this complication.
Metrics
Details
- Title
- Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery
- Creators
- Baha Sibai - University of CincinnatiPaul J. Meis - Wake Forest UniversityMark Klebanoff - National Institutes of HealthMitchell P. Dombrowski - Wayne State UniversitySteven J. Weiner - George Washington UniversityAtef H. Moawad - University of ChicagoAllison Northen - University of Alabama at BirminghamJay D. Iams - The Ohio State UniversityMichael W. Varner - University of UtahSteve N. Caritis - University of PittsburghMary J. O'Sullivan - University of Miami*Menachem Miodovnik - Columbia UniversityKenneth J. Leveno - The University of Texas at DallasDeborah Conway - The University of Texas at San AntonioRonald J. Wapner - Drexel UniversityMarshall Carpenter - Brown UniversityBrian Mercer - Case Western Reserve UniversitySusan M. Ramin - The University of Texas at AustinJohn M. Thorp - University of North CarolinaAlan M. Peaceman - Northwestern UniversitySteven Gabbe - VA Medical Centerfor the Maternal Fetal Medicine Units Network of the National Institute of Child Health and Human DevelopmentDaniel H Conway - Pediatrics
- Publication Details
- American journal of obstetrics and gynecology, v 193(3), pp 1181-1186
- Publisher
- Mosby, Inc
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000232013700050
- Scopus ID
- 2-s2.0-24644480139
- Other Identifier
- 991019168575604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Obstetrics & Gynecology